KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Depreciation and Depletion: 2009-2025

Historic Depreciation and Depletion for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to $10.6 million.

  • Biomarin Pharmaceutical's Depreciation and Depletion fell 2.75% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.9 million, marking a year-over-year increase of 2.63%. This contributed to the annual value of $46.6 million for FY2024, which is 15.63% up from last year.
  • Biomarin Pharmaceutical's Depreciation and Depletion amounted to $10.6 million in Q3 2025, which was down 0.00% from $10.6 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Depreciation and Depletion peaked at $14.1 million during Q1 2025, and registered a low of $8.7 million during Q3 2022.
  • For the 3-year period, Biomarin Pharmaceutical's Depreciation and Depletion averaged around $11.1 million, with its median value being $10.7 million (2023).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Depreciation and Depletion tumbled by 41.91% in 2021 and then rose by 22.99% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Depreciation and Depletion (Quarterly) stood at $10.4 million in 2021, then dropped by 16.35% to $8.7 million in 2022, then increased by 22.99% to $10.7 million in 2023, then increased by 8.41% to $11.6 million in 2024, then decreased by 2.75% to $10.6 million in 2025.
  • Its Depreciation and Depletion stands at $10.6 million for Q3 2025, versus $10.6 million for Q2 2025 and $14.1 million for Q1 2025.